Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-984923 Single-Ascending Dose Study in Healthy Volunteers
NCT04805983Phase 1Completed
- Sponsor
- Yale University
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-9894923 in Alzheimer's disease (AD) (6 arms), sponsored by Yale University. Primary endpoints: Treatment Emergent Adverse Events, Laboratory Abnormalities and 4 more. Started Mar 2021; status: completed.
02
Drugs
BMS-9894923
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04805983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805983.